Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
Future Oncology
Volume 9, Issue 6, Pages 889-897
Publisher
Future Medicine Ltd
Online
2013-05-29
DOI
10.2217/fon.13.39
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peg-filgrastim and cabazitaxel in prostate cancer patients
- (2012) Giuseppe Di Lorenzo et al. ANTI-CANCER DRUGS
- New Perspectives in the Therapy of Castration Resistant Prostate Cancer
- (2012) Pasquale Rescigno et al. CURRENT DRUG TARGETS
- Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme
- (2012) Axel Heidenreich et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
- (2011) Andrew J. Armstrong et al. EUROPEAN UROLOGY
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
- (2011) Eleni Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Castration-Resistant Prostate Cancer
- (2010) Giuseppe Di Lorenzo et al. DRUGS
- Prostate cancer incidence and mortality trends in 37 European countries: An overview
- (2010) F. Bray et al. EUROPEAN JOURNAL OF CANCER
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Docetaxel Rechallenge in Castration-Resistant Prostate Cancer: Scientific Legitimacy of Common Clinical Practice
- (2010) Carlo Buonerba et al. EUROPEAN UROLOGY
- Sipuleucel-T for prostate cancer: the immunotherapy era has commenced
- (2010) Carlo Buonerba et al. Expert Review of Anticancer Therapy
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
- (2009) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now